April 15 (Reuters) - Eli Lilly and Co LLY.N:
SKYE BIOSCIENCE DEMONSTRATES OVER 30% WEIGHT LOSS WITH NIMACIMAB AND TIRZEPATIDE COMBINATION IN PRECLINICAL MODEL
SKYE BIOSCIENCE INC - NIMACIMAB SHOWS ADDITIVE WEIGHT LOSS EFFECT WITH TIRZEPATIDE IN DIO MODEL
SKYE BIOSCIENCE INC - NIMACIMAB PHASE 2A TOP-LINE DATA EXPECTED LATE Q3/EARLY Q4 2025
SKYE BIOSCIENCE INC - NIMACIMAB AND TIRZEPATIDE COMBINATION SHOWS >30% WEIGHT LOSS
SKYE BIOSCIENCE INC - NIMACIMAB ALONE SHOWS 23.5% WEIGHT LOSS
Source text: ID:nGNX5vMw83
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.